A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
NCT07927010, Phase 2, Phase 3, Not yet recruiting, Mighty Therapeutics, Inc.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD) | ClinicalTrials.gov |
| NCT number | NCT07927010 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2, Phase 3 | ClinicalTrials.gov |
| Enrollment | 300 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Mighty Therapeutics, Inc. | ClinicalTrials.gov |
| Conditions | Dry AMD, Age-Related Macular Degeneration (AMD) | ClinicalTrials.gov |
| Interventions | 1 % Bevemipretide, 2% Bevemipretide, Vehicle | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Rate of Change in Macular Area of Photoreceptor Loss through week 48 | 48 Weeks | Rate of change in the macular area of photoreceptor loss (defined as an Ellipsoid Zone - Retinal Pigment Epithelium (EZ-RPE) thickness of 0μm) through Week 48, assessed by spectral domain optical coherence tomography (SD-OCT) and Ellipsoid Zone (EZ) mapping | ClinicalTrials.gov |
| Secondary | Rate of Change in the macular area of partial photoreceptor loss | 48 Weeks | Rate of change in the macular area of partial photoreceptor loss (defined as an EZ-RPE thickness of ≤ 20 μm) through Week 48, assessed by SD-OCT and EZ mapping | ClinicalTrials.gov |
| Secondary | Proportion of Subjects gaining ≥ 10 letters (2 lines) in Low Luminance Best Corrected Visual Acuity (LL BCVA) from baseline | 48 Weeks | Proportion of subjects gaining ≥ 10 letters (2 lines) in Low Luminance Best Corrected Visual Acuity (LL BCVA) from baseline at Week 48, assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart | ClinicalTrials.gov |
| Secondary | Proportion of subjects gaining ≥ 15 letters (3 lines) in LL BCVA from baseline | 48 Weeks | Proportion of subjects gaining ≥ 15 letters (3 lines) in LL BCVA from baseline at Week 48, assessed by the ETDRS chart | ClinicalTrials.gov |
| Secondary | Change in low luminance quantitative contrast sensitivity function | 48 weeks | Change from baseline in low luminance quantitative contrast sensitivity function (qCSF) at Week 48 | ClinicalTrials.gov |
| Secondary | Proportion of subjects gaining ≥ 5 letters (1 line) in LL BCVA at week 48 | 48 Weeks | Proportion of subjects gaining ≥ 5 letters (1 line) in LL BCVA from baseline at Week 48, assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart | ClinicalTrials.gov |
| Secondary | Proportion of subjects losing < 5 letters (1 line) in LL BCVA at Week 48, | 48 weeks | Proportion of subjects losing \< 5 letters (1 line) in LL BCVA from baseline at Week 48, assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart | ClinicalTrials.gov |
| Secondary | Proportion of subjects losing < 10 letters (2 lines) in LL BCVA at Week 48 | 48 weeks | Proportion of subjects losing \< 10 letters (2 lines) in LL BCVA from baseline at Week 48, assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart | ClinicalTrials.gov |
| Secondary | Proportion of subjects losing < 15 letters (3 lines) in LL BCVA at Week 48 | 48 weeks | Proportion of subjects losing \< 15 letters (3 lines) in LL BCVA from baseline at Week 48, assessed by the ETDRS chart | ClinicalTrials.gov |
| Secondary | Change in LL BCVA letter score at Week 48 | 48 weeks | Change in LL BCVA letter score from baseline at Week 48, assessed by the ETDRS chart | ClinicalTrials.gov |
| Secondary | Change in LL BCVA Deficit at Week 48 | 48 weeks | Change in LL BCVA Deficit (LLD, defined as the difference between BCVA and LL BCVA) from baseline at Week 48, assessed by the ETDRS chart | ClinicalTrials.gov |
| Secondary | Change in standard luminance qCSF at Week 48 | 48 weeks | Change from baseline in standard luminance qCSF at Week 48 | ClinicalTrials.gov |
| Secondary | Safety Assessments: Incidence and Severity of adverse Events | 52 weeks | Report the # of subjects with adverse events and incidence and severity of such adverse events (AEs) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Contrast Sensitivity Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)